Physis International LLC is a New Albany drug-repurposing pharmaceutical company built around a scientifically experienced team in oncology and clinical development. Its work focuses on immune modulation, particularly changing macrophage behavior to support therapies for cancer and inflammatory disease, while helping move promising treatments through clinical and regulatory processes.
Human Subjects and Materials in Clinical Research
compliance_program
Decedent Materials in Research Policy
compliance_program
Data Security
compliance_program
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV
Protheragen IncFounded in New York, Protheragen Inc. is a biopharmaceutical incubator that helps turn early-stage drug discoveries into commercial assets. Its integrated approach combines project incubation, early-stage capital support and cross-border business-development consulting, linking scientists and pharmaceutical companies with international partners. The company says it has more than 18 years of industry experience and has managed over 130 projects, with a particular focus on oncology programs.HOLBROOK, NY
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA